Adding Cetuximab to chemo doubles response rate in hard-to-treat breast cancer

[News]

European researchers have proven for the first time that targeting the epidermal growth factor receptor can provide substantial clinical benefit for women with hard-to-treat triple-negative breast cancer.

More... (http://www.news-medical.net/news/20101011/Adding-Cetuximab-to-chemo-doubles-response-rate-in-hard-to-treat-breast-cancer.aspx)